Page 77 - MEMOCiberes014-ENG

• Study of the impact of RD8 on the regulation of ESAT-6 secretion in Mycobacterium bovis and My- cobacterium africanum.SecRegulTBC. REFBIO. 2013- 2014 • Antimicrobial resistance, virulence and new therapies in bacterial human pathogens. REFBIO 2013- 2014 • Network: European reference laboratory network for tuberculosis (ERLTB-Net) - to strengthen TB diagnosis, drug susceptibility tes- ting and coordination at European Union level . Ref: GRANT/2013/003 . ECDC . Fecha inicio: 2014 .
• Line 3: MM4TB More Medicines for Tuberculosis . European Union Organization Chief Researcher and Coordinator: José Antonio Ainsa. 2011-2014 • NAREB - Nanotherapeutics for antibiotic resistant emerging bacterial pathogens European Union . 2014- 2018 .
Most relevant scientific articles
• Lee r.e., hurdLe J.G., LIu J., BruhN d.F., Matt t., ScherMaN M.S. et al . Spectinamides: A new class of semisynthetic antituberculosis agents that overcome native drug efflux . Nature Medicine . 2014;20(2):152-158 .
• GoNzaLo-aSeNSIo J., MaLaGa W., paWLIk a., aStarIe-dequeker c., paSSeMar c., Moreau F. et al . Evolutionary history of tuberculosis shaped by conserved mutations in the PhoPR virulence regulator . Proceedings of the National Academy of Sciences of the United States of America . 2014;111(31):11491-11496 .
• SoLaNS L., GoNzaLo-aSeNSIo J., SaLa c., BeNJak a., upLekar S., rouGeMoNt J. et al . The PhoP-Dependent ncRNA Mcr7 Modulates the TAT Secretion System in Mycobacterium tuberculosis . PLoS Pathogens . 2014;10(5):- .
• aGuILó N., uraNGa S., MarINoVa d., MartIN c., pardo J. . Bim is a crucial regulator of apoptosis induced by Mycobacterium tuberculosis . Cell Death and Disease . 2014;5(7):- .
• aLLIx-BeGuec c., WahL c., haNekoM M., NIkoLaYeVSkYY V., droBNIeWSkI F., Maeda S. et al . Proposal of a con- sensus set of hypervariable mycobacterial interspersed repetitive-unit-variable-number tandem-repeat loci for subtyping of mycobacterium tuberculosis Beijing isolates . Journal of Clinical Microbiology . 2014;52(1):164-172 .
Highlights
ACTIVE PROJECTS IN 2014
• MM4TB More Medicines for Tuberculosis. European Union Organization. Chief Researcher and Coordinator: José Antonio Ainsa • NAREB Nanotherapeutics for antibiotic resistant emerging bacterial pathogens. European Union Organization. Chief Researcher and Coordinator: José Antonio Ainsa • BIO2011-23555 Project: “Study of the mechanisms of protection of MTBVAC and its potential use as recombinant polyvalent vaccine .” MCyT/DGI/FEDER Organization 2012-2014 Chief Researcher and Coordinator: Carlos Martín • INNPACTO: Ref. IPT-2012-0327-090000. Vacuna Inactivada contra la tuberculosis en base a una cepa modificada genéticamente Ministerio de Economía y Competitividad Organization . Universidad de Zaragoza, Universidad Complutense and Biofabri . Chief Researcher and Coordination: Carlos Martín • Polimorfismos genómicos y transcriptómicos en M. tuberculosis complex y su significado en clínica . FIS, Instituto de Salud Carlos III Organization Chief Researcher and Coordination: Sofía Samper • Study of the impact of RD8 on the regulation of ESAT-6 secretion in My- cobacterium bovis and Mycobacterium africanum . SecRegulTBC . REFBIO Organization Chief Resear- cher and Coordination: Sofía Samper • Patent Number P2014/30421 2014/03/25. Spain.Inventors: Carlos Martin, Brigitte Gicquel, Luis Solans, Nacho Aguilo, Santiago Uranga Title: Triple mutant of Mycobacterium tuberculosis Complex erp-, phoP- Y DIM Zaragoza University • Clinical Trials: “Dose- Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine .” ClinicalTrials .gov Identifier: NCT02013245
Institution: Universidad de Zaragoza Contact: Universidad de Zaragoza . C/ Pedro Cerbuna, 12 . 50009 Zaragoza Phone: (+34) 976 761 759 · E .mail: carlos@unizar .es · Website: genmico .unizar .es
www.ciberes.org 77